Assembly Biosciences, Inc. (NASDAQ:ASMB) – Stock analysts at William Blair issued their Q1 2018 EPS estimates for shares of Assembly Biosciences in a research note issued to investors on Monday. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will earn ($0.96) per share for the quarter. William Blair also issued estimates for Assembly Biosciences’ Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.74) EPS and Q4 2018 earnings at ($0.78) EPS.
ASMB has been the subject of several other research reports. Jefferies Group LLC started coverage on shares of Assembly Biosciences in a research note on Wednesday, November 8th. They issued a “buy” rating and a $50.00 target price for the company. Chardan Capital reiterated a “buy” rating on shares of Assembly Biosciences in a research note on Sunday, September 17th. BidaskClub upgraded shares of Assembly Biosciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 24th. Finally, Zacks Investment Research upgraded shares of Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 10th.
Assembly Biosciences (NASDAQ ASMB) opened at $33.34 on Tuesday. Assembly Biosciences has a 12 month low of $11.07 and a 12 month high of $36.31.
Hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $161,000. Parametric Portfolio Associates LLC boosted its position in shares of Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 1,203 shares during the period. Legal & General Group Plc bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $212,000. Wells Fargo & Company MN bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $213,000. Finally, Trexquant Investment LP bought a new position in shares of Assembly Biosciences in the second quarter valued at approximately $217,000. Institutional investors own 62.19% of the company’s stock.
In other news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total value of $29,550.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 19.60% of the stock is currently owned by company insiders.
About Assembly Biosciences
Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.
Receive News & Ratings for Assembly Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.